AMGN - Amgen Inc.
| Previous close | 220.86 |
| Open | 221.06 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 219.25 - 221.52 |
| 52-week range | 166.30 - 225.26 |
| Volume | 2,239,516 |
| Avg. volume | 2,465,555 |
| Market cap | 131.119B |
| Beta (3Y monthly) | 1.10 |
| PE ratio (TTM) | 16.97 |
| EPS (TTM) | 13.00 |
| Earnings date | 27 Jan 2020 - 31 Jan 2020 |
| Forward dividend & yield | 5.80 (2.63%) |
| Ex-dividend date | 2019-11-14 |
| 1y target est | 222.27 |
- Zacks
Bristol-Myers Gets FTC Clearance for Celgene Acquisition
Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
- Zacks
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
- Zacks
Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength
Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.
- Reuters - UK Focus
FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target
The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters. The company, which has seen its market value jump fivefold to $6 billion over the past four years, is now pivoting its strategy to in-house research, using its technology that allows it to create libraries of peptide chemicals that can bind drugs to cells.
- Zacks
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
Style Box ETF report for FTCS
- Zacks
Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength
Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
- Zacks
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
- Zacks
Top Analyst Reports for Verizon, McDonald's & TOTAL
Top Analyst Reports for Verizon, McDonald's & TOTAL
- Zacks
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View
Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
- Zacks
Biotech ETFs in Focus on Impressive Q3 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
- Zacks
Value Biotech ETFs & Stocks to Buy Now
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
- Zacks
What's in the Cards for Teva (TEVA) This Earnings Season?
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
- Zacks
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
- Zacks
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View
AbbVie (ABBV) beats on both earnings and revenues in the third quarter. The company ups the lower end of its 2019 guidance for adjusted earnings per share.
- Bloomberg
Amgen to Take $2.7 Billion Stake in BeiGene for China Growth
(Bloomberg) -- Amgen Inc. will take a 20.5% stake in Chinese-American drug developer BeiGene Ltd. under a deal to develop and commercialize about two dozen of Amgen’s on-market and experimental cancer drugs in China.Amgen will buy about $2.7 billion worth of Beijing and Cambridge, Massachusetts-based BeiGene’s shares. It has agreed to pay $174.85 per American depositary receipt, a 26% premium to where the U.S.-traded shares closed Wednesday. It will also take a seat on BeiGene’s board.BeiGene’s shares rose 32%, the most on record, in Hong Kong on Friday. The ADRs rose 27% in post-market trading in New York on Thursday, while Amgen was little changed.Under the agreement, BeiGene will take over Chinese commercialization of three drugs used to treat cancer and its effects: Xgeva, which is already on the market in China, and Kyprolis and Blincyto, which are near approval. The companies will equally split any profit or loss.“We’ve been working to expand our strategy geographically over the last four or five years,” Murdo Gordon, Amgen executive vice president of global commercial operations, said in a telephone interview. “We’re largely complete in that, and this is really the missing piece of the puzzle.”BeiGene will also work to develop and commercialize 20 of Amgen’s experimental oncology drugs. BeiGene will put in $1.25 billion for that effort, and Thousand Oaks, California-based Amgen will help fund development and pay royalties on the products if Amgen sells them outside of China.What Bloomberg Intelligence Says:“The deal will expand BeiGene’s oncology portfolio and further build its presence in China, while the proceeds will extend BeiGene’s cash runway beyond 2020.”\- Cinney Zhang, BI analyst wrote in a Nov. 1 note.China’s pharmaceutical market has transformed under the government’s efforts to bring in more new, brand-name medicines. As the government has agreed to approve and pay for new treatments, drugmakers have shifted their focus from selling older pills that have lost patent protection in Western markets and are increasingly working on developing and commercializing newer products in China. Cancer drugs have been a particular focus, both for domestic Chinese companies and multinational drugmakers anxious to tap the massive market.“This deal wouldn’t have happened if it wasn’t for these regulatory reforms in China that have led to a boom in the domestic biotech space,” said BeiGene’s China President Wu Xiaobin.BeiGene already has a large footprint in China, Chief Executive Officer John Oyler said in a phone interview. Out of its about 3,000 total workers, 2,300 are in China, with 700 in sales and another 600 in clinical development.Oyler said the company has been expanding its sales and research operations in China for years in anticipation that the market would grow and become more inviting of new drugs. “We realized that was going to happen, and we built out these deep capabilities in front of it,” Oyler said.‘Vote of Confidence’Amgen’s investment is also “a strong vote of confidence against the short selling” that hurt BeiGene’s shares in September, according to Wu. J. Capital Research called BeiGene “poorly managed” in a report early that month. The company rebutted the report, saying it had “numerous inaccurate, unfounded and misleading allegations.”Under the agreement, Amgen isn’t allowed to build a larger stake without permission, the companies said in telephone interviews. Amgen’s Chief Financial Officer David Meline said the companies didn’t discuss an acquisition of BeiGene.The agreement is expected to close in early 2020, the companies said. Goldman Sachs Group Inc. was Amgen’s financial adviser, and Latham & Watkins LLP gave legal advice. BeiGene’s financial adviser was Morgan Stanley.(Updates with comments from BeiGene executives in the eighth paragraph)To contact the reporters on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net;Dong Lyu in Beijing at dlyu3@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Bhuma ShrivastavaFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Zacks
Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise
Celgene (CELG) beats on earnings and revenues in the third quarter of 2019 on strong performance from Otezla and Revlimid.
- Zacks
Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates
Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.
- Zacks
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
- Zacks
Amgen (AMGN) Beats on Q3 Earnings, Ends Neuroscience R&D
Amgen (AMGN) posts encouraging third-quarter 2019 results. It raises its previously issued sales guidance slightly while increasing the earnings range significantly.
- Zacks
Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.
- Simply Wall St.
Does Amgen Inc.'s (NASDAQ:AMGN) CEO Salary Compare Well With Others?
Bob Bradway became the CEO of Amgen Inc. (NASDAQ:AMGN) in 2012. This analysis aims first to contrast CEO compensation...
- Zacks
Amgen (AMGN) Q3 Earnings and Revenues Top Estimates
Amgen (AMGN) delivered earnings and revenue surprises of 4.27% and 1.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
Amgen posts higher biosimilar sales, ends neuroscience program
The biotechnology company, which last year launched migraine drug Aimovig, also said it would end programs to develop other neuroscience drugs. Amgen posted third-quarter adjusted earnings per share of $3.66, beating the average analyst estimate by 13 cents, according to IBES data from Refinitiv. Share buybacks lowered the number of Amgen shares outstanding by 7% from a year earlier.
- Investing.com
Amgen Earnings, Revenue Beat in Q3
Investing.com - Amgen (NASDAQ:AMGN) reported third quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.
